The presence of systemic inflammation in patients with advanced pancreatic cancer may point to possible resistance to CD40 agonists, according to findings from a new study.
The presence of systemic inflammation in patients with advanced pancreatic cancer may point to possible resistance to CD40 agonists, according to findings from a new study.